Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [18F]fluciclatide kinetics and [15O]H2O PET

EJNMMI Research

Table 2 Kinetic parameters for [ ¹⁵ O]H ₂ O and [ ¹⁸ F]fluciclatide at the VOI level

Patient number	K₁[¹⁵O]H₂O	k₂[¹⁵O]H₂O	k₃/k₄[¹⁸F]fluciclatide	SUVfluci DELIVERY	SUVfluci RETENTION
	(mL/cm³/min)	(L/min)	(unitless)	(m²/L)	(m²/L)
1	0.15	0.32	4.34	0.070	0.049
2	0.16	0.38	4.37	0.137	0.072
3	0.38	0.61	4.87	0.045	0.064
4	N/A	N/A	7.81	0.050	0.087
5	N/A	N/A	6.57	0.040	0.070
6	0.68	0.88	N/A	N/A	N/A
(Tumor#1)
6	0.39	0.62	N/A	N/A	N/A
(Tumor#2)	0.39	0.62	N/A	N/A	N/A
7	0.44	0.72	4.38	0.077	0.062